When the Tumor Returns: Why Salvage Treatment Cannot Be One-Size-Fits-All
If you or someone you love has just been told your glioblastoma has returned, everything changes. The standard treatment path — surgery, radiation, temozolomide chemotherapy — is now behind you. The question now is harder: which treatment, for this tumor, at this time.
The word salvage treatment is direct. At recurrence, doctors choose from fewer options and there's no single standard plan. One thing is critical but often overlooked: your tumor's current biological profile — specifically, how it responds to different drugs.
Drug sensitivity analysis can help answer this question. Understanding what it does, what it shows, and how it fits into a broader precision-oncology assessment can help you and your care team make better decisions.
Why Recurrence Changes Everything at the Molecular Level
Glioblastoma is genetically unstable. From the start, cells accumulate different mutations at different rates and in different locations. A sample from one part of the tumor may look different from tissue taken just a few centimetres away. This is called intratumoral heterogeneity. It's one reason glioblastoma resists single treatments.
At recurrence, it gets more complex. Treatment creates biological selection pressure. Some cells naturally resist radiation or temozolomide and survive. When the tumor regrows, treatment-resistant cells usually drive it. Research on molecular mechanisms of drug resistance in glioblastoma shows recurrent tumors often have new molecular changes, including changes to DNA repair pathways, receptor signalling, and the tumor microenvironment, that weren't there at initial diagnosis.
This is the core problem. You may be targeting a disease that has changed. A salvage decision based only on the original pathology report is like fighting with a map of old terrain.
What Drug Sensitivity Analysis Actually Examines
Standard molecular profiling (the type most patients get at diagnosis) identifies which genetic mutations are in the tumor. This is useful. But it doesn't show how the tumor actually responds to specific drugs.
Drug sensitivity analysis — sometimes called functional precision medicine — goes further. Instead of just mapping mutations, it exposes living tumor cells to different drugs in lab conditions and measures which ones stop growth or kill cells. The result is a drug response profile specific to that tumor at that time.
A feasibility study published in PMC tested this approach in recurrent glioblastoma stem cells. Using drug sensitivity testing on 525 anticancer compounds, researchers found big differences in how individual tumors responded — even if the tumors looked similar on regular tests. What stopped growth in one tumor did little in another. Standard molecular markers alone couldn't predict these differences.
Here's what this means: a tumor's actual drug response may differ from what its genetic features alone would suggest. Functional testing gives information that genetic sequencing alone can't.
The Gap Between Standard Reports and Current Tumor Reality
Most patients with glioblastoma receive standard pathology reports with certain markers — MGMT methylation status, IDH mutation, EGFR amplification. These markers matter. MGMT methylation status helps predict how the tumor responds to temozolomide — important at initial treatment and when considering it again at recurrence.
Several problems arise when relying only on these reports at recurrence. First, some recurrent tumors show molecular changes not in the original tumor — including shifts in MGMT methylation and changes in DNA repair gene expression. A report from the original surgery may not reflect what's driving the current tumor.
Second, standard reports usually come from one biopsy. Given spatial heterogeneity in glioblastoma, this may miss groups of cells that respond differently to drugs. A pilot study on glioblastoma treatment using whole exome sequencing found that WES can identify molecular changes that standard tests miss — potentially showing targets or pathways worth discussing for clinical trials or other treatment options.
Third, standard reports are diagnostic. They weren't made to guide salvage treatment. Turning them into useful treatment plans at recurrence needs different expertise and often different analysis.
Whole Exome Sequencing and RNA Sequencing at Recurrence
Whole exome sequencing (WES) looks at protein-coding regions of the tumor genome. It can identify mutations, copy number changes, and structural variations across thousands of genes — much more than standard tests. RNA sequencing adds more information: it shows which genes are active in the tumor right now, showing the pathways driving growth and resistance.
Together, WES and RNA sequencing can show the tumor's molecular type, find possible treatment targets, and inform clinical trial discussions. A precision neuro-oncology pilot study in recurrent glioma found that using molecular profiling in treatment discussions led to more personalized decisions — important when few standard options exist and the tumor's biology determines which approaches might work.
When combined with drug sensitivity analysis, these sequencing approaches show: the genetics (WES), the active molecular pathways (RNA sequencing), and the drug response profile (sensitivity testing). This combination gives a complete picture of the tumor — not just one test, but multiple tests together to inform treatment decisions.
Liquid Biopsy: Tracking the Tumor Between Imaging Scans
Another tool to understand is liquid biopsy — detection of circulating tumor DNA (ctDNA) or other tumor signals in blood or cerebrospinal fluid. When a second biopsy isn't possible, liquid biopsy can monitor tumor changes over time and between MRI scans, and can spot resistance as it develops.
Understanding circulating tumor DNA and liquid biopsy monitoring in glioblastoma is important for patients with recurrent disease — it works with, not instead of, imaging surveillance.
How This Information May Support Salvage Treatment Discussions
At recurrence, options typically include re-surgery where possible, re-irradiation, alternative chemotherapy, anti-angiogenic agents, Tumor Treating Fields, and clinical trials. Understanding what each agent does in recurrent glioblastoma — who it helps and what the evidence shows — is one conversation to have.
The challenge is no one option works for all patients. Success rates vary by tumor biology. A clinical trial examining molecular profiling to guide individualized treatment plans in recurrent glioblastoma shows that each tumor's biology — not a standard plan — should drive treatment choices where possible.
Drug sensitivity analysis and comprehensive molecular profiling can support these discussions by giving a stronger biological reason for one approach over another. The goal is to support your oncologist's judgment with a stronger foundation — especially when standard reports don't answer important questions.
What International Patients and Families Need to Know
Access to comprehensive tumor analysis varies by institution and country. Many patients — in London, Manchester, Birmingham, New York, Sydney, Melbourne, Toronto, Dubai, Berlin, and elsewhere — find their local center doesn't offer drug sensitivity testing or full precision-oncology review as standard.
This is why many families seek an independent expert review at this stage — to work with their local team and make sure their tumor's current biology is fully understood before major decisions. Location doesn't limit analysis quality. Pathology reports, test results, MRI scans, and surgical notes can all be reviewed remotely by specialists experienced in glioblastoma tumor biology.
Patients from across the United Kingdom, United States, Australia, Canada, Germany, France, New Zealand, and the UAE have found that an online expert review before starting treatment helped them have better conversations with their oncologists. Expertise in precision oncology isn't determined by location.
What Reports Should You Gather Before Seeking an Expert Review?
If you're considering an independent precision-oncology review of your recurrent glioblastoma, gathering these documents will help the assessment be as complete as possible:
- Pathology Report — from original surgery and, if available, from any re-biopsy at recurrence
- Histopathology Report — including grading, morphological features, and immunohistochemistry results
- MRI Brain Reports — especially post-contrast sequences from the most recent scan and prior comparisons
- Surgical Notes — from all procedures, including documented extent of resection
- Molecular Testing Results — MGMT, IDH, EGFR, TERT, PTEN, and any next-generation sequencing panels already performed
- Current Treatment Plan — what is being proposed by your local oncology team at recurrence
- Previous Treatment History — all prior chemotherapy regimens, radiation details, and any clinical trial participation
The more complete this picture, the more meaningful a precision-oncology review can be — and the more useful it may prove for your own treating team when deciding the next step.
Common Mistakes Families Make at Recurrence
The weeks after a recurrence diagnosis are very difficult. In that rush, families often make certain mistakes they later regret:
- Assuming the tumor is the same as at diagnosis. The recurrent tumor often changes at the molecular level. Treatment based on old reports may not match the current tumor.
- Accepting the first salvage option without exploring alternatives. No single approach works for all recurrent glioblastomas. Understanding why each option might work — and whether clinical trials fit — is important before deciding.
- Not seeking independent expert review. Your local oncologist knows your history, but may not have access to the full tumor analysis you need. A second opinion reviewed remotely can give more clarity without much cost in time or effort.
- Waiting too long to gather reports. Molecular testing, sequencing, and expert reviews take time. Starting early to gather documents and get input preserves more options.
Questions to Ask Your Oncology Team at Recurrence
- Has the tumor been molecularly tested at recurrence, or are decisions based on the original pathology?
- What molecular changes may have occurred since the initial diagnosis?
- Has drug sensitivity analysis been considered? Is it available here?
- Which open clinical trials match this tumor's molecular profile?
- Would whole exome sequencing or RNA sequencing add actionable information for my situation?
- Has this been reviewed by a tumor board with recurrent glioblastoma experts?
Taking the Next Step
Every glioblastoma is biologically unique. At recurrence, that uniqueness becomes more important for the treatment decisions ahead. A review of your pathology reports, test results, MRI scans, and surgical notes may show insights worth discussing with your care team.
Many families get expert analysis before choosing a salvage strategy. International patients often start with a virtual consultation and report review — practical, no travel needed, and it provides a foundation for better discussions with their doctors. Understanding your tumor's current biology can help you have clearer conversations with your team about next steps.
If you or a loved one is facing recurrent glioblastoma, gathering your pathology reports, MRI scans, surgical notes, and test results is a good first step. A team with glioblastoma expertise can review your case, identify biological insights, and help you understand what to ask your doctors.
When to Talk to Your Doctor
If imaging shows recurrence, or if your doctor mentions disease progression, ask about molecular testing and precision-oncology analysis. If drug sensitivity testing, WES, or RNA sequencing haven't been discussed, ask about them. Your current tumor's biology, not just the original profile, should guide the treatment decisions ahead.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.